OnKure Therapeutics Inc [OKUR] stock is trading at $2.9, up 1.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The OKUR shares have gain 2.47% over the last week, with a monthly amount glided 2.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on December 05, 2024, and set its price target to $33. On October 10, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $35 on the stock. Leerink Partners downgraded its rating to a Market Perform. Jefferies downgraded its rating to a Hold. H.C. Wainwright downgraded its rating to Neutral for this stock on December 15, 2023, and downed its price target to $1.50. In a note dated December 14, 2023, William Blair downgraded an Mkt Perform rating on this stock.
OnKure Therapeutics Inc [OKUR] stock has fluctuated between $1.70 and $9.40 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. OnKure Therapeutics Inc [NASDAQ: OKUR] shares were valued at $2.9 at the most recent close of the market. An investor can expect a potential return of 1106.9% based on the average OKUR price forecast.
Analyzing the OKUR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.91, Equity is -0.78 and Total Capital is -1.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.67 points at the first support level, and at 2.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.11, and for the 2nd resistance point, it is at 3.33.
Ratios To Look Out For
For context, OnKure Therapeutics Inc’s Current Ratio is 11.45. On the other hand, the Quick Ratio is 11.45, and the Cash Ratio is 11.26.
Transactions by insiders
Recent insider trading involved Saccomano Nicholas A, President and CEO, that happened on Dec 22 ’25 when 87.0 shares were sold. Chief Financial Officer, Leverone Jason A. completed a deal on Dec 22 ’25 to sell 302.0 shares. Meanwhile, President and CEO Saccomano Nicholas A sold 88.0 shares on Sep 22 ’25.
